

Khaled S Abd-Elrahman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2262257/publications.pdf>

Version: 2024-02-01

38
papers

712
citations

566801

15
h-index

580395

25
g-index

39
all docs

39
docs citations

39
times ranked

720
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Neuroglial Metabotropic Glutamate Receptors in Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2023, 21, 273-283.	1.4	10
2	Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 235-254.	4.2	36
3	A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female <sc>APP ^{swE} </sc>/PSEN1 ^{T9} mice. <i>British Journal of Pharmacology</i> , 2022, 179, 1769-1783.	2.7	14
4	Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 801757.	1.4	11
5	Early metabolic impairment as a contributor to neurodegenerative disease: Mechanisms and potential pharmacological intervention. <i>Obesity</i> , 2022, 30, 982-993.	1.5	11
6	VGLUT3 ablation differentially modulates glutamate receptor densities in mouse brain. <i>ENeuro</i> , 2022, , ENEURO.0041-22.2022.	0.9	1
7	Optineurin deletion disrupts metabotropic glutamate receptor 5-mediated regulation of ERK1/2, GSK3 β /ZBTB16, mTOR/ULK1 signaling in autophagy. <i>Biochemical Pharmacology</i> , 2021, 185, 114427.	2.0	15
8	The pleiotropic effects of antithrombotic drugs in the metabolic "cardiovascular" neurodegenerative disease continuum: impact beyond reduced clotting. <i>Clinical Science</i> , 2021, 135, 1015-1051.	1.8	9
9	Sex-biased mGluR5 pharmacology and pathophysiological signaling in Alzheimer's disease. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
10	Ablation of optineurin impairs metabotropic glutamate receptor 5 signaling in mouse hippocampus. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
11	Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 74-84.	1.3	12
12	mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 1418-1431.	1.9	25
13	Targeting VGLUT Machinery: Implications on mGluR5 Signaling and Behavior. <i>Molecular Pharmacology</i> , 2020, 98, MOLPHARM-MR-2020-000089.	1.0	14
14	mGluR5 regulates REST/NRSF signaling through N-cadherin/ β -catenin complex in Huntington's disease. <i>Molecular Brain</i> , 2020, 13, 118.	1.3	20
15	Targeting Vesicular Glutamate Transporter Machinery: Implications on Metabotropic Glutamate Receptor 5 Signaling and Behavior. <i>Molecular Pharmacology</i> , 2020, 98, 314-327.	1.0	2
16	A β oligomers induce pathophysiological mGluR5 signaling in Alzheimer's disease model mice in a sex-selective manner. <i>Science Signaling</i> , 2020, 13, .	1.6	45
17	mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 334-344.	2.5	34
18	Podocyte NADPH Oxidase 5 Promotes Renal Inflammation Regulated by the Toll-Like Receptor Pathway. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1817-1830.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Structural determinants governing β -arrestin2 interaction with PDZ proteins and recruitment to CRFR1. <i>Cellular Signalling</i> , 2019, 63, 109361.	1.7	9
20	Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs. <i>Translational Research</i> , 2019, 214, 121-143.	2.2	27
21	Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice. <i>Molecular Brain</i> , 2019, 12, 35.	1.3	67
22	mGluR5 regulates ZBTB16 pathway of autophagy in Alzheimer's disease in a sex-specific manner. <i>FASEB Journal</i> , 2019, 33, 810.5.	0.2	1
23	Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models. <i>Molecular Brain</i> , 2018, 11, 19.	1.3	38
24	GRK2 knockdown in mice exacerbates kidney injury and alters renal mechanisms of blood pressure regulation. <i>Scientific Reports</i> , 2018, 8, 11415.	1.6	10
25	Metabotropic glutamate receptor 5 (mGluR5) blockade ameliorates Huntington's disease pathology via activating convergent mechanisms of autophagy. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR24-3.	0.0	0
26	Abnormal myosin phosphatase targeting subunit 1 phosphorylation and actin polymerization contribute to impaired myogenic regulation of cerebral arterial diameter in the type 2 diabetic Goto-Kakizaki rat. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 227-240.	2.4	17
27	mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington's disease. <i>Science Signaling</i> , 2017, 10, .	1.6	70
28	ROK and Arteriolar Myogenic Tone Generation: Molecular Evidence in Health and Disease. <i>Frontiers in Pharmacology</i> , 2017, 08, 87.	1.6	20
29	Vascular Smooth Muscle-Specific EP4 Receptor Deletion in Mice Exacerbates Angiotensin II-Induced Renal Injury. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 642-656.	2.5	12
30	PKC-mediated cerebral vasoconstriction: Role of myosin light chain phosphorylation versus actin cytoskeleton reorganization. <i>Biochemical Pharmacology</i> , 2015, 95, 263-278.	2.0	34
31	Abnormal Rho-associated kinase activity contributes to the dysfunctional myogenic response of cerebral arteries in type 2 diabetes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2015, 93, 177-184.	0.7	17
32	PPAR δ Dependence of Cyclosporine-Isoprenaline Renovascular Interaction: Roles of Nitric Oxide Synthase and Heme Oxygenase. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 173-180.	0.8	10
33	Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. <i>Biochemical Pharmacology</i> , 2011, 81, 526-533.	2.0	36
34	Role of PPAR δ /Nitric Oxide Synthase Signaling in the Cyclosporine-induced Attenuation of Endothelium-dependent Renovascular Vasodilation. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 195-202.	0.8	7
35	Stromatoxin-sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter. <i>Journal of Physiology</i> , 2010, 588, 4519-4537.	1.3	52
36	Improved Antioxidant And Lipid Profiles Underlie The Protective Effect Of Pioglitazone Against Cyclosporine-Induced Endothelium Dysfunction In Isolated Rat Aortas. <i>FASEB Journal</i> , 2010, 24, 961.13.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Pioglitazone Ameliorates Cyclosporine-Induced Attenuation Of Carbachol Renovascular Vasodilations: Role Of PPAR ^γ /Nitric Oxide Synthase Signaling. FASEB Journal, 2010, 24, 959.11.	0.2	0
38	Amyloid β Oligomers Induce Sex-Specific Pathophysiological mGluR5 Signaling in Alzheimer Mice. SSRN Electronic Journal, 0, , .	0.4	4